Akero Therapeutics Inc said on Monday its experimental therapy reduced liver fat by 65% in a mid-stage study of patients with a type of fatty liver disease called nonalcoholic steatohepatitis (NASH).
The drug, efruxifermin, also met secondary goals as 88% of patients' absolute liver fat level normalized to 5 percent or less, compared to 10% treated with a type of diabetes drug alone, Akero said in a statement.
Editor's Note: New Aging Research Reveals Key to Long, Healthy Life
Data from the study showed the drug was safe and well-tolerated amongst patients, with most frequent adverse events related to use include diarrhea, nausea, and increased appetite.
Drug developer plans to commence two late-stage studies of the therapy later this year.